US EditionWuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year
- WuXi Biologics has received the 2025 CDMO Leadership Awards in the 'Biologics- Global' category, marking its eighth consecutive year of recognition.
- The company excelled in categories such as 'Best Scientific Expertise' and 'Best Innovative Approach to Technology and Process Execution.'
- WuXi Biologics reduced monoclonal antibody project development time to 9 months, with some projects completed in just 6 months.
- Chris Chen, CEO of WuXi Biologics, stated that this award reflects their team's dedication to delivering treatments effectively.
Insights by Ground AI
Does this summary seem wrong?
49 Articles
49 Articles
All
Left
2
Center
14
Right
3
The Berkshire Eagle+47 Reposted by 47 other sources
WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year
SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been…
Coverage Details
Total News Sources49
Leaning Left2Leaning Right3Center14Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
11%
C 74%
R 16%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
